Risk factors for symptomatic Avascular Necrosis (AVN) in a multi-ethnic Systemic Lupus Erythematosus (SLE) cohort

Syahrul Sazliyana Shaharir, Siew Huoy Chua, Rozita Mohd, Ruslinda Mustafar, Malehah Mohd Noh, Nor Shuhaila Shahril, Mohd Shahrir Mohamed Said, Sakthiswary Rajalingham

1 Rheumatology Unit, Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia, 2 Department of Internal Medicine, International Medical University, Kuala Lumpur, Malaysia, 3 Nephrology Unit, Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia, 4 Department of Medicine, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia, 5 Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia

These authors contributed equally to this work.

* sazliyana@ukm.edu.my, syahrul.sazliyana.shaharir@ppukm.ukm.edu.my

Abstract

Avascular necrosis of bone (AVN) is increasingly being recognized as a complication of SLE and causes significant disability due to pain and mobility limitations. We studied the prevalence and factors associated with avascular necrosis (AVN) in a multiethnic SLE cohort. SLE patients who visited the outpatient clinic from October 2017 to April 2019 were considered eligible. Their medical records were reviewed to identify patients who developed symptomatic AVN, as confirmed by either magnetic resonance imaging or plain radiography. Subsequently, their SLE disease characteristics and treatment were compared with the characteristics of patients who did not have AVN. Multivariable logistic regression analyses were performed to determine the independent factors associated with AVN among the multiethnic SLE cohort. A total of 390 patients were recruited, and the majority of them were females (92.6%); the patients were predominantly of Malay ethnicity (59.5%), followed by Chinese (35.9%) and Indian (4.6%). The prevalence of symptomatic AVN was 14.1%, and the mean age of AVN diagnosis was 37.6 ± 14.4 years. Both univariate and multivariable logistic regression analyses revealed that a longer disease duration, high LDL-C (low density lipoprotein cholesterol), positive anti-cardiolipin (aCL) IgG and anti-dsDNA results, a history of an oral prednisolone dose of more than 30 mg daily for at least 4 weeks and osteoporotic fractures were significantly associated with AVN. On the other hand, hydroxychloroquin (HCQ), mycophenolate mofetil (MMF) and bisphosphonate use were associated with a lower risk of AVN. No associations with ethnicity were found. In conclusion, several modifiable risk factors were found to be associated with AVN, and these factors may be used to identify patients who are at high risk of developing such complications. The potential protective effects of HCQ, MMF and bisphosphonates warrant additional studies.
Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by multisystem organ inflammation that leads to tissue damage. SLE predominantly affects young women of reproductive age and is associated with a high morbidity rate due to the underlying disease and immunosuppressive treatment. Osteonecrosis or avascular necrosis of the bone (AVN) has been increasingly detected as a complication from SLE since it was first described in 1960 [1]. It usually progresses to irreversible joint damage, causing significant disability due to pain and mobility limitations.

The interruption of blood supply to the bones is the underlying pathogenesis of AVN, and the most commonly affected site is the epiphysis of the femur [2]. Histologically, it is characterized by subchondral bone necrosis as a result of end artery supply to the bone being compromised. The prevalence of symptomatic avascular necrosis (AVN) is reported to be from 0.8%–33%, and that of asymptomatic AVN is reported to be 29–45% among systemic lupus erythematosus (SLE) patients [3]. These large differences in prevalence are due to differences in the study methodology and disease characteristics and sociodemographic backgrounds of the study populations.

Corticosteroids have traditionally been considered the most important risk factor for AVN in SLE [3]; however, AVN has also long been observed in SLE patients who have not been administered corticosteroids [4]. Moreover, high disease activity in the year prior to AVN clinical diagnosis is considered the main independent factor for the development of AVN in SLE [5]. In addition, several other noncorticosteroid-related risk factors for AVN in SLE have been reported, such as arthritis, CNS involvement, diabetes mellitus, hypertension, oral ulcers, renal involvement, vasculitis, a smoking history, leucopenia, thrombocytopenia, cytotoxic drugs and cyclophosphamide [6]. Antiphospholipid syndrome is considered to be one of the risk factors of developing AVN, but conflicting results have been reported in SLE studies.

Avascular necrosis (AVN) is the most frequent condition that occurred in the musculoskeletal system in the local cohort included in our study [7]. US studies have reported a higher prevalence of AVN among African American individuals [8, 9]. Multiethnic studies are scarce, but the Monash Lupus Clinic database demonstrated that there was a trend toward a higher risk of AVN among Asian patients than among non-Asian patients [10]. Therefore, we conducted this study to determine the modifiable risk factors for AVN among a multiethnic Asian SLE population.

Methodology

Patients

This was a retrospective study involving patients who visited the UKM Medical Centre (UKMMC) and Putrajaya Hospital from October 2017 to April 2019. All patients fulfilled the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria 2012 [11]. Patients with incomplete medical records and patients who had overlap SLE with other connective tissue disease were excluded from the study. Their medical records were reviewed to identify patients with avascular necrosis (AVN). The diagnosis of AVN was confirmed by imaging, i.e., magnetic resonance imaging (MRI) or radiography. The period from the SLE diagnosis to AVN diagnosis was recorded. Information on the patient’s demographic background (age, sex) and disease characteristics, such as age of onset, disease duration, organ/system involvement, and presence of antiphospholipid antibodies (anti-cardiolipin and lupus anticoagulant), were retrieved from the medical records. The presence of corticosteroid-related complications or damage was recorded, including i) cardiovascular damage, ii)
glucocorticoid-induced osteoporosis (GIOP) with fractures, iii) cataracts and iv) corticoste-
roid-induced diabetes mellitus (CDM).

The medical and prescription records were also reviewed to retrieve the following informa-
tion on the medication use and treatment of the subjects:

1. cumulative dose of corticosteroids, defined as the sum of the cumulative prednisolone dose
   and methylprednisolone dose converted to the prednisolone dose.
2. use of more than 30 mg of oral prednisolone daily (>30 mg a day) for at least 4 weeks.
3. use of other immunosuppressants, e.g., azathioprine, mycophenolate mofetil (MMF) and
cyclosporine A (CyA), defined as the continuous use of the medications for at least 6
   months at the optimum or recommended dose.
4. use of anti-malarial (hydroxychloroquine or chloroquine), defined as the continuous use of
   a high daily dosage of hydroxychloroquine (i.e., mean daily dosage over the exposure period
   \( \geq 100 \) mg for chloroquine and \( \geq 200 \) mg for hydroxychloroquine) for at least 1 year [12].
5. use of a bisphosphonate agent for prophylaxis of GIOP, as per recommended by the guide-
   lines [13].
6. use of statins to treat dyslipidemia.

For patients with AVN, the above immunosuppressive and treatment information recorded
until the date of AVN diagnosis was retrieved. Moreover, for patients without AVN, the infor-
mation recorded until the last clinic visit was retrieved. Subjects with incomplete treatment
records were excluded from the analysis.

This study was approved by the Research and Ethics Committee of the Universiti Kebang-
saan Malaysia Medical Center (UKMMC) and Ministry of Health Malaysia (Approval code:
FF-2017-425 and NMRR-17-2346-35987). The requirement for informed consent was waived
by both ethics committees.

**Statistical analyses**

The quantitative variables are reported as the mean and standard deviation (SD) or median
and range (minimum-maximum), depending on the normality of the distributions. The nor-
mality of the data was assessed with the Kolmogorov-Smirnov test. The absolute and relative
frequencies are reported for the categorical variables. AVN patients were evaluated at the time
of AVN diagnosis, while other patients were evaluated at the last visit to the clinic during the
study period. The incidence rate of AVN was calculated as the number of AVN cases divided
by the sum of years of follow-up from the onset of SLE until AVN diagnosis (for AVN cases)
or to the last visit to the clinic (for patients without AVN). The SLE clinical and laboratory
characteristics were compared between the patients with AVN and without AVN by univariate
analysis using \( \chi^2 \) or Fisher’s exact tests (if one or more of the variable values had an expected
frequency of five or less) for the categorical variables. In addition, for the continuous variables,
independent Student’s t-tests or Mann-Whitney tests were performed, depending on the nor-
mality of the data. For comparisons of continuous variables across three or more groups, one-
way analysis of variance (ANOVA) was used for normally distributed variables, while the
Kruskal-Wallis test was used for nonnormally distributed variables. Multivariable logistic
regression analyses were also performed by including all variables that were significant in the
univariate analyses, with \( p < 0.05 \), to determine the independent factors associated with AVN
in SLE. Analyses were performed using SPSS, version 21.0 (SPSS Inc. Chicago IL, USA).
Results

A total of 28 subjects were excluded due to incomplete treatment records, and a total of 390 patients were finally included, with a mean age at the time of study recruitment of 42.8 ± 12.6 years and a disease duration of 16.3 ± 6.8 years. The majority of the patients were females (n = 361, 92.6%), and most were of Malay ethnicity (n = 232, 59.5%), followed by Chinese (n = 140, 35.9%) and Indian (n = 18, 4.6%). More than half of the patients in this cohort had musculoskeletal (65.1%), renal (63.1%) and haematological (60.5%) involvement. A total of 187 patients with LN had renal biopsy. The commonest WHO class of LN was proliferative class III and IV (with or without class V) which affected 76 patients (40.6%) respectively. A total of 22 patients (11.7%) had pure class V LN while 11 (5.88%) had LN class II, and 1 (0.53%) patients each had class I and VI. A total of 11 patients (2.8%) had end stage renal disease (ESRD) and one of them developed AVN 10 years before the onset of ESRD. Seven patients (1.8%) had ischaemic heart disease with one of them had AVN. Three (0.7%) had heart failure and one of them had AVN.

The Chinese patients who were included in this study had longer disease duration, had more LN and anti-dsDNA antibodies than did the Malay and Indian patients (p < 0.05). Anti-phospholipid syndrome (APLS) tended to occur more commonly among the Indian patients (p = 0.06). Table 1 illustrates the baseline demographics and disease characteristics of the SLE patients according to their ethnicity.

Prevalence and factors associated with avascular necrosis (AVN)

The point prevalence of avascular necrosis in this study was 14.1% (n = 55), and the overall incidence rate was 9.77 per 1000 patient-years at the follow-up. There was a gradual decline in the incidence rate of AVN, with the calculated incidence rate from the period of 1990–1999 was 29.3 per 1000 patient-years, followed by 13.49 per 1000 patient-years in 2000–2009 and 8.04 per 1000 patient-years in 2010–2019. Majority of the patients had femoral AVN (n = 52, 94.5%). Two patients (3.6%) had AVN involving both femorals and knees while only 1 patient (1.8%) had AVN of the right humeral head. The mean age at onset of AVN was 37.6 ± 14.4 years. The mean disease duration prior to AVN onset was 7.5 ± 6.5 years, with a median of 5 (0.5–29) years. The majority of the patients were in remission when AVN was diagnosed (n = 40, 72.7%) and were taking a median dose of 10 (0–60) mg of oral prednisolone.

The patients who had AVN were significantly older at the time of recruitment and had a longer disease duration, both p < 0.05. A significantly higher prevalence of AVN was found among the patients who tested positive for anti-cardiolipin (aCL) IgG, anti-dsDNA, high LDL-C (Low density lipoprotein cholesterol), the patients who had previously received oral prednisolone doses > 30 mg a day and the patients with a history of osteoporotic fractures (all p < 0.05). On the other hand, the patients who received treatment with hydroxychloroquine, azathioprine and mycophenolate mofetil (MMF) had significantly fewer cases of AVN, all p < 0.05. A significantly lower AVN prevalence was also found in the patients who had received bisphosphonates for prophylaxis against corticosteroid-induced osteoporosis (CIOP), p = 0.01.

There was a possibility of the osteoporotic fracture and the use of bisphosphonate groups being less mutually exclusive. This is because as up to 70.6% (n = 24) of patients with osteoporotic fractures received bisphosphonate treatment while only 41% (n = 146) of patients who have no history of osteoporotic fractures received bisphosphonate as prophylaxis against fracture. However, after excluded patients with osteoporotic fracture, the use of bisphosphonate was still significantly associated with a lower prevalence of AVN. A total of 17 (40.5%) patients with AVN had ever received bisphosphonate therapy while 25 patients (59.5%) of the patients
with AVN have not received bisphosphonate treatment, p = 0.012. Table 2 illustrates the factors associated with AVN among the SLE cohort.

In the logistic regression analysis, which included all variables that had a p value of $\leq 0.05$ in the univariate analyses, the independent factors associated with AVN were aCL IgG positive, anti-dsDNA positive, dyslipidemia, an osteoporotic fracture and a prednisolone dose $> 30$ mg daily. On the other hand, the use of HCQ, MMF and bisphosphonates were associated with a lower risk of AVN (Table 3). The logistic regression model explained 41.9% (Nagelkerke $R^2$) of the variance in AVN and correctly classified 86.1% of the cases.

**Discussion**

Symptomatic AVN was detected in 14.1% of the SLE patients in our study, which is consistent with the prevalence (12%) reported in other Asian studies [14, 15]. The reported prevalence of symptomatic AVN varies between 0.8% and 33% [3]. An explanation for this discrepancy could be that there is variability in the AVN diagnostic tools, including MRI, conventional radiography and computed tomography, and there are differences in the study methodology.
Table 2. Sociodemographic and disease characteristics associated with avascular necrosis among SLE patients.

| Variable                        | No AVN (n = 335) | AVN (n = 55) | p     |
|---------------------------------|------------------|--------------|-------|
| Age, mean ± SD (years)          | 42.1 ± 12.3      | 47.6 ± 13.3  | 0.002 |
| Age at onset (years)            | 29.9 ± 11.8      | 30.6 ± 12.2  | 0.70  |
| Disease duration, mean ± SD (years) | 15.6 ± 11.2    | 20.4 ± 8.8   | <0.001|
| Sex, n (%)                      |                  |              |       |
| Male                            | 25 (7.5)         | 4 (7.3)      |       |
| Female                          | 310 (92.5)       | 51 (92.7)    | 1.00  |
| Ethnicity, n (%)                |                  |              |       |
| Malay                           | 202 (60.3)       | 30 (54.5)    | 0.51  |
| Chinese                         | 119 (35.5)       | 21 (38.2)    |       |
| Indian                          | 14 (4.2)         | 4 (7.3)      |       |
| System/Organ, n (%)             |                  |              |       |
| Lupus Nephritis                 | 211 (63.0)       | 35 (63.6)    | 1.00  |
| Hematological                   | 201 (60.0)       | 35 (63.6)    | 0.66  |
| Musculoskeletal                 | 217 (64.8)       | 37 (67.3)    | 0.76  |
| Mucocutaneous                   | 156 (46.6)       | 28 (50.9)    | 0.56  |
| Neuropsychiatric Lupus          | 42 (12.5)        | 9 (16.4)     | 0.39  |
| Antiphospholipid syndrome       | 23 (6.9)         | 4 (7.3)      | 1.00  |
| Vasculitis                      | 58 (17.3)        | 13 (23.6)    | 0.26  |
| Proliferative LN\(b\), n (%)   | 130 (81.8)       | 23 (85.2)    | 0.79  |
| aCL IgG positive\(c\), n (%)   | 72 (21.8)        | 20 (37.0)    | 0.02  |
| aCL IgM positive\(c\), n (%)   | 56 (17.0)        | 12 (22.2)    | 0.34  |
| Lupus anticoagulant\(d\), n (%)| 33 (10.7)        | 5 (10.2)     | 1.00  |
| Anti-dsDNA positive, n (%)      | 237 (70.7)       | 46 (83.6)    | 0.05  |
| Immunosuppressants, n (%)       |                  |              |       |
| Corticosteroid use              | 328 (97.9)       | 53 (96.4)    | 0.37  |
| Cyclophosphamide                | 163 (48.7)       | 22 (40.0)    | 0.25  |
| Mycophenolate Mofetil           | 152 (45.4)       | 12 (21.8)    | 0.001 |
| Azathioprine                    | 219 (65.4)       | 28 (50.9)    | 0.05  |
| Ciclosporine A                  | 131 (39.1)       | 17 (30.9)    | 0.29  |
| Cumulative corticosteroid, mean ± SD (g) | 32.9 ± 26.6 | 29.7 ± 45.3 | 0.45  |
| Prednisolone > 30 mg a day\(e\), n (%) | 103 (30.7)      | 35 (63.6)    | <0.001|
| Hydroxychloroquine, n (%)       | 279 (83.4)       | 25 (45.5)    | <0.001|
| Bisphosphonate, n (%)           | 208 (62.1)       | 26 (47.3)    | 0.05  |
| Corticosteroid-damage, n (%)    |                  |              |       |
| Cardiovascular event            | 27 (8.1)         | 5 (9.1)      | 0.79  |
| CDM                             | 33 (9.9)         | 8 (14.5)     | 0.34  |
| Osteoporosis with fracture      | 21 (6.3)         | 13 (23.6)    | <0.001|
| Cataract                        | 26 (7.8)         | 4 (7.3)      | 1.00  |
| Hypertension, n (%)             | 170 (50.7)       | 29 (52.7)    | 0.88  |
| High LDL-C, n (%)               | 60 (17.9)        | 18 (32.7)    | 0.02  |
| High Triglyceride, n (%)        | 78 (23.3)        | 19 (34.5)    | 0.09  |

\(a\) at the time of study recruitment.
\(b\) renal biopsy available in 187 patients.
\(c\) results available in 384 patients.
\(d\) results available in 358 patients.
\(e\) prednisolone > 30 mg a day use for at least 4 weeks.

aCL = anticardiolipin, LDL-C = Low density lipoprotein cholesterol, LN = lupus nephritis, CDM = corticosteroid-induced diabetes mellitus, SD = standard deviation.
Our study has demonstrated a gradual decline in the incidence rate of AVN over several decades and a similar finding was also observed in a SLE cohort in Hong Kong [16]. An improvement in overall SLE management and the detection of harmful high-dose corticosteroids may have contributed to this decrease in incidence.

Ethnicity may influence individuals’ risk of developing AVN, as African-American patients, including pediatric SLE [3, 17] and kidney transplant patients [18], are particularly predisposed to developing AVN. Several Asian studies have also reported a high rate of AVN, higher than 20%, in areas including Thailand, China, and Hong Kong [16, 19, 20], while the AVN prevalence has been reported to be less than 10% in Caucasian-predominant cohorts [4, 21–29]. Although AVN complications in SLE may merely reflect more severe underlying diseases that require high doses of corticosteroids, a recent study has revealed a possible genetic influence, suggesting that certain ethnicities may be predisposed to developing such complications. For instance, Apolipoprotein L1 (APOL1) variant alleles, and not corticosteroids, were associated with AVN among African American patients with lupus [30]. Moreover, the presence of Multidrug-resistant transporter-1 (MDR1) 3435 TT genotypes was associated with a lower incidence of AVN among Chinese patients with lupus [31]. Genetic variants in the Apolipoprotein L1 (APOL1) gene are found only in individuals with African ancestry. It is one of six members of the APOL gene family on human chromosome located on chromosome 22q12.3. It has an innate immune function which regulates intracellular death and APOL1 gene is associated with an excess risk of chronic and end stage kidney disease [32], as well as atherosclerotic disease in SLE [33]. Meanwhile, Multidrug-resistant transporter-1 (MDR1) gene is located on human chromosome 7 band q21.1. It encodes P-glycoprotein (P-gp), which acts as an energy-dependent membrane efflux pump for various drugs including steroids. It influences the pharmacokinetics of steroids and their metabolites through the pump regulation in absorption and distribution of the drugs at intracellular and extracellular levels. Subsequently this may lead to individual differences in steroid response and sensitivity [34].

Corticosteroid (CS) use has the most robust association with AVN in SLE. The pathogenesis of CS-associated osteonecrosis is not fully understood, but ischemia is the principal pathogenesis of AVN. Fat embolism, an increased intraosseous pressure due to fat cell hypertrophy, vasoconstriction and a reduction in mesenchymal stem cells with corticosteroid therapy are few of the pathomechanisms of corticosteroid-induced AVN [35]. Instead of the cumulative

Table 3. Multivariable logistic regression analysis of the independent factors associated with avascular necrosis in SLE.

| Parameters                      | B Coefficient | OR (95% CI)  | P     |
|---------------------------------|---------------|--------------|-------|
| Age                             | 0.01          | 1.01 (0.98–1.04) | 0.53  |
| Disease duration                 | 0.05          | 1.05 (1.00–1.11) | 0.05  |
| Hydroxychloroquine use          | -1.39         | 0.25 (0.11–0.54) | <0.001 |
| Osteoporosis with fracture       | 1.48          | 4.41 (1.55–12.56) | 0.005 |
| Anti-cardiolipin IgG positive    | 1.08          | 2.95 (1.35–6.44) | 0.007 |
| Anti-dsDNA positive             | 1.25          | 3.49 (1.34–9.09) | 0.011 |
| Prednisolone > 30 mg daily      | 1.34          | 3.84 (1.81–8.11) | <0.001 |
| Mycophenolate mofetil use       | -1.53         | 0.22 (0.08–0.57) | 0.002 |
| Azathioprine use                | -0.11         | 0.91 (0.41–1.98) | 0.79  |
| Bisphosphonate use              | -1.15         | 0.32 (0.14–0.74) | 0.007 |
| High LDL-C                      | 1.27          | 3.55 (1.53–8.24) | 0.003 |

CI = confidence interval, OR = odds ratio.
Nagelkerke $R^2$ values = 0.419.

https://doi.org/10.1371/journal.pone.0248845.t003
dose, the mean daily or peak dose has been shown to be strongly associated with the AVN dose in a meta-analysis [36]. Our study results concur with the above finding, as no significant associations with cumulative corticosteroid use were found; few patients develop AVN as early as within the first year of SLE diagnosis. The consumption of more than 30 mg of prednisolone daily for at least 4 weeks increased individuals’ risk of developing AVN by 4 times.

However, in SLE, the disease itself, apart from corticosteroids, predisposes patients to developing AVN complications to a greater extent than do other autoimmune chronic diseases with corticosteroid therapy [37]. This finding suggests that the use of corticosteroids may not be the only risk factor associated with the development of AVN in SLE patients. In agreement with this, our study showed that the presence of anti-cardiolipin IgG was one of the predictors of AVN, which is consistent with the results of a few other studies [38, 39]. However, the majority of other studies showed that SLE patients who tested positive for aCL IgM were particularly predisposed to developing AVN complications [3]. Indeed, AVN is recognized as one of the osteoarticular features in primary APLS [40]; thus, it is important to monitor this complication in SLE patients with antiphospholipid antibodies.

A significant association between corticosteroid-induced osteoporosis (CIOP) and AVN in SLE suggests a shared pathogenesis between these complications. Both complications are well known to be associated with corticosteroids in patients with SLE, and there is a significant association between osteopenia and AVN in kidney transplant patients [41]. However, most importantly, our study findings suggest that the use of bisphosphonates as a prophylactic treatment against CIOP may also be beneficial in preventing AVN among SLE patients. Animal studies have demonstrated that bisphosphonates (alendronate) improves the trabecular bone and microcirculation of the femoral head and prevents corticosteroid-induced femoral head AVN in rats [42]. Currently, there are no data on the protective role of bisphosphonates in humans, but there is a small amount of evidence from noncontrolled studies showing that bisphosphonates may play a role in relieving the symptoms of patients who have developed non-femoral head AVN, delaying disease progression and surgery [43]. Thus, in addition to the findings of these studies, our findings suggest that larger clinical trials should be conducted to determine the effectiveness of bisphosphonates in preventing hip AVN.

Another interesting finding to note is that hydroxychloroquine (HCQ) and mycophenolate mofetil (MMF) may have protective effects against hip AVN in SLE patients. There are conflicting results on the protective effect of HCQ. Few studies have demonstrated lower rates of AVN in HCQ-treated patients [15, 19, 39, 44, 45], but a meta-analysis failed to detect such associations [3]. The use of immunosuppressants such as MMF, azathioprine and methotrexate in SLE patients has not been shown to be associated with a higher risk of AVN, except for cyclophosphamide [3]. In contrast, studies among patients who have undergone a hematopoietic transplant showed that the exposure to MMF and calcineurin inhibitors increased their risk of AVN [46].

Dyslipidemia has been reported to be associated with AVN in SLE [14, 17], as intraosseous fat cell hypertrophy and fat embolism are involved in the pathogenesis of AVN. Our study findings concurred with their findings. Patients with LN, especially those with nephrotic range proteinuria, and patients on corticosteroid therapy are indeed predisposed to lipid derangements. A retrospective study reported that statins may lower the risk of AVN in patients who previously received high-dose corticosteroid therapy [47], but additional larger prospective studies are warranted to confirm the effectiveness of statins in preventing AVN.

Our study has several limitations, including its retrospective nature, which leads to many biases. Only symptomatic AVN was diagnosed in this study, and AVN can be asymptomatic in many patients, especially if it occurs at the knees and ankles, and the incidence is when asymptomatic patients are included [3]. In addition, our study did not examine other possible risk
factors, such as vitamin D deficiency [48] and obesity [49]. Nevertheless, we revealed several important potential management approaches for preventing AVN among patients with SLE by identifying the risk factors and several potential protective effects of the common medications used in treating SLE patients.

Supporting information

S1 Appendix. Raw data.

Author Contributions

Conceptualization: Syahrul Sazliyana Shaharir, Ruslinda Mustafar.

Data curation: Syahrul Sazliyana Shaharir, Malehah Mohd Noh, Nor Shuhaila Shahril.

Formal analysis: Syahrul Sazliyana Shaharir, Rozita Mohd.

Funding acquisition: Syahrul Sazliyana Shaharir.

Writing – original draft: Syahrul Sazliyana Shaharir, Siew Huoy Chua.

Writing – review & editing: Ruslinda Mustafar, Mohd Shahrir Mohamed Said, Sakthiswary Rajalingham.

References

1. E. Dubois LC. Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. J Am Med Assoc. 1960; 174:966–8.
2. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct; 32(2):94–124. PMID: 12430099
3. Nevskaya T, Gamble MP, Pope JE. A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):700–10. PMID: 28240590
4. Abeles M, Urman JD, Rothfield NF. Aseptic Necrosis of Bone in Systemic Lupus Erythematosus: Relationship to Corticosteroid Therapy. Arch Intern Med. 1978; 138(5):750–4. PMID: 646538
5. Fialho SC, Bonfa E, Vitule LF, D’Amico E, Caparbo V, Gualandro S, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus. 2007; 16(4):239–44. https://doi.org/10.1177/0961203307076771 PMID: 17439929
6. Tao Wang ZL, Xingfu Li. Non-corticosteroid-related risk factors for osteonecrosis in patients with systemic lupus erythematosus: a meta-analysis. Int J Clin Exp Med 2016; 9 (5):8085–96.
7. Shaharir SS, Hussein H, Rajalingham S, Mohamed Said MS, Abdul Gafor AH, Mohd R, et al. Damage in the Multiethnic Malaysian Systemic Lupus Erythematosus (SLE) Cohort: Comparison with Other Cohorts Worldwide. PLoS One. 2016; 11(11):e0166270. https://doi.org/10.1371/journal.pone.0166270 PMID: 27846298
8. Reut Gurion HY, Hong Li, Stephanie Frenkian, Kathleen A. Haines, Jennifer E. Weiss, Yukiko Kimura, et al. Risk factors for the development of avascular necrosis in pediatric systemic lupus erythematosus patients. Arthritis Rheum. 2013; 65:S536–S7.
9. Olsen NJ, Youssif M, Mutwally A, Cory M, Elmagboul N, Karp DR. Organ damage in high-risk patients with systemic and incomplete lupus syndromes. Rheumatol Int. 2013 Oct; 33(10):2585–90. https://doi.org/10.1007/s00296-013-2793-3 PMID: 23715694
10. Goldner V, Connelly K, Staples M, Morand E, Hol A. Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus. 2013 Nov; 22(13):1425–30. https://doi.org/10.1177/09612033135000547 PMID: 23942610
11. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism. 2012; 64(8):2677–86. https://doi.org/10.1002/art.34473 PMID: 22553077
12. Fardel L, Nazareth I, Petersen I. Effects of chronic exposure of hydroxychloroquine/chloroquine on the risk of cancer, metastasis, and death: a population-based cohort study on patients with connective
tissue diseases. Clin Epidemiol. 2017; 9:545–54. https://doi.org/10.2147/CLEP.S143563 PMID: 29138600

13. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis & Rheumatology. 2017 Aug; 69(8):1521–37. https://doi.org/10.1002/art.40137 PMID: 28585373

14. Ono K, Tohjima T, Komazawa T. Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clin Orthop Relat Res. 1992 Apr (277):89–97. PMID: 1555361

15. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol. 1998 Aug; 37(8):895–900. https://doi.org/10.1093/rheumatology/37.8.895 PMID: 9734882

16. Tse SM, Mok CC. Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus. Lupus. 2017; 26(7):715–22. https://doi.org/10.1177/0961203316676384 PMID: 27831540

17. Gurion R, Tangpricha V, Yow E, Schanberg LE, McComsey GA, Robinson AB, et al. Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatr Rheumatol Online J. 2015; 13:13–. https://doi.org/10.1186/s12969-015-0008-x PMID: 25902709

18. Abbott KC, Oglesby RJ, Agodoa LY. Hospitalized avascular necrosis after renal transplantation in the United States. Kidney International. 2002 2002/12/01/; 62(6):2250–6. https://doi.org/10.1046/j.1523-1755.2002.00667.x PMID: 12427153

19. Abbot KC, Oglesby RJ, Agodoa LY. Hospitalized avascular necrosis after renal transplantation in the United States. Kidney International. 2002; 62(6):2250–6. https://doi.org/10.1046/j.1523-1755.2002.00667.x PMID: 12427153

20. LI X RQ, CHEN Z, LI X, WANG G, Risk factors for avascular necrosis in patients with systemic lupus erythematosus. Int J Rheum Dis. 2013; 16(Suppl. 1):1–48.

21. Cozen L, Wallace DJ. Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. Am J Orthop (Belle Mead NJ). 1998 1998/05 //; 27(5):352–4. PMID: 9604106

22. Asherson RA, Liote F, Page B, Meyer O, Buchan an N, Khamashta MA, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol. 1993 Feb; 20 (2):284–8. PMID: 8474066

23. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients. Medicine (Baltimore). 2003; 82(5):299–308.

24. Rascu A, Manger K, Kraetsch HG, Kalden JR, Manger B. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus. 1996 Aug; 5(4):323–7. https://doi.org/10.1177/096120339600500414 PMID: 8869906

25. Yip K EE, Qian Y, Clancy R, Buyon J, Blazer A. Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol 2019; 71 (suppl 10).

26. Yang XY, Xu DH. MDR1(ABCB1) gene polymorphisms associated with steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie. 2007 Dec; 62(12):930–2. PMID: 18214345
32. Friedman DJ, Pollak MR. APOL1 Nephropa thy: From Genetics to Clinical Applications. Clinical Journal of the American Society of Nephrology. 2021; 16(2):294–303. https://doi.org/10.2215/CJN.15161219 PMID: 32616495

33. Blazer A, Wang B, Simpson D, Kirchoff T, Heffron S, Clancy RM, et al. Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. PLoS One. 2017; 12(8):e0182483. https://doi.org/10.1371/journal.pone.0182483 PMID: 28850570

34. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003 Jul; 4(4):397–410. https://doi.org/10.1517/phpgs.4.4.397.22747 PMID: 12831320

35. Chan KL, Mok CC. Glucocorticoid-induced avascular bone necrosis: diagnosis and management. Open Orthop J. 2012; 6:449–57. https://doi.org/10.2174/1874325001208010449 PMID: 23115605

36. Felson D, Anderson J. ACROSS-STUDY EVALUATION OF ASSOCIATION BETWEEN STEROID DOSE AND BOLUS STEROIDS AND AVASCULAR NECROSIS OF BONE. The Lancet. 1987 1987/04/18; 329(8538):902–6. https://doi.org/10.1016/s0140-6736(87)92870-4 PMID: 2882300

37. Shigemura T, Nakamura J, Kishida S, Harada Y, Ohtori S, Kamikawa K, et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology. 2011; 50(11):2023–8. https://doi.org/10.1093/rheumatology/ker277 PMID: 21865285

38. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997 Apr; 24(4):654–62. PMID: 9101497

39. Al Saleh J, El Sayed M, Salah N, Harb D, Khan N, Mohammed N. Predictors of avascular necrosis of the hip in Emiratis patients with systemic lupus erythematosus. Egypt J Immunol. 2010; 17(1):29–40. PMID: 22053607

40. Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, Kelekos DA, Moutsopoulos HM. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum. 2003 Mar; 48(3):732–6. https://doi.org/10.1002/art.10835 PMID: 12632427

41. Paydas S, Balal M, Demir E, Sertdemir Y, Erken U. Avascular osteonecrosis and accompanying anemia, leucocytosis, and decreased bone mineral density in renal transplant recipients. Transplant Proc. 2011 Apr; 43(3):863–6. https://doi.org/10.1016/j.transproceed.2011.02.072 PMID: 21486616

42. Junhui Yin SW, Yixuan Chen, Wen Zhang, Youshui Gao. Alendronate prevents glucocorticoid-induced osteonecrosis of the femoral head in rats. Int J Clin Exp Med. 2017; 10(7):1033–42.

43. Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol. 2001; 28(4):761–5. PMID: 11327247

44. Campbell S, Sun C-L, Kurian S, Francisco L, Carter A, Kulkarni S, et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer. 2009; 115(18):4127–35. https://doi.org/10.1002/cncr.24474 PMID: 19536905

45. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001 May(386):173–8. https://doi.org/10.1097/00003086-200105000-00022 PMID: 11347831

46. Gurion R, Tangpricha V, Yow E, Schanberg LE, McComsey GA, Robinson AB, et al. Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatric Rheumatology. 2015 2015/04/23; 13(1):13. https://doi.org/10.1186/s12969-015-0008-x PMID: 25902709

47. Feltner R, Perrin P, Caillard S, Moulin B, Javier R-M. Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. PLoS One. 2019; 14(2):e0212931. https://doi.org/10.1371/journal.pone.0212931 PMID: 30794689